The current revolution in immuno-oncology is being driven by Antibody Drug Conjugates, Immune Checkpoint Inhibitors, Bispecific Antibodies and Cell Therapies. Clinical trials have showed that cancer patients can tolerate this immune-based treatment more effectively than conventional treatments like chemotherapy and radiotherapy. It’s clearly one of the hottest fields of Biopharma which has gained momentum in the past few years.
Focused on the impact of two technologies on manufacturers, our conference is going one step further by addressing a series of application-based illustrations and discussions to map the future possibility of trends in the manufacturing world.
Improving clinical translation in neuroscience research has always been a major challenge until now. There are many research collaborations happening in the neuroscience space today for neurodegenerative disorders research. The conference will focus on discussing the latest technologies in the preclinical, translational neuroscience space and also drawing the attention of the audience towards new innovations happening in translational neuroscience imaging. The conference further aims to bring in the experts from academia and industry together to discuss how to create new, more effective translational neuroscience drawing on novel technology and recent discoveries.
Biomarker is constantly evolving as the latent for the development of innovative drugs and diagnostic assays for early detection of disease. The major developments are witnessed in immune therapies where breakthroughs will be appearing soon. The conference will address the gaps between early stage biomarker development and the commercialization stage of biomarkers. Regarding commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to the clinical translation of biomarkers.
While most of the molecular studies focus over mutational analysis, epigenetics-is the only science which is gaining momentum with its cheaper and faster technology, by making its way to the clinic. Moving on the path of clinical epigenetics, this congress will discuss the solutions to challenges like, drug discovery, identification of molecular inhibitors, gene modification and analysis.
With the increasing recognition of real-world data opportunities and challenges within the pharmaceutical and biotech industry, life sciences organizations face clear decisions on how specifically to put resources into real-world evidence capacities. Real-World Evidence can possibly change the way life sciences associations use advancements to increase further clinical bits of knowledge and enable them and payers to collaborate like never before. After the successful inaugural, this year’s congress will hold discussions on accelerating the adoption of Real-world Evidence within the industry while understanding the capabilities of newer technologies for evidence generation.
Where does your success begin? With constant development emerging in global marketing scenario, things have become far more complicated then it seems. Smarter marketing solutions opted by the Chief Marketing professionals give the holistic view over the depth of any industry, economically and ideologically. These solutions help organizations improve their measurement and strategic planning. Smarter the solutions, better the outcomes.
District cooling is one of the nine strategic pillars in Dubai Supreme Council of Energy’s Demand Side Management strategy, towards achieving 30% power savings in the emirate by 2030. The major steps for enhancing district cooling adoption includes planning and educating the top players in real estate firms on the advantages and guiding on the knowledge of technical know-how.
This conclave aims to provide a platform to experts from Government bodies, regulatory authorities, real estate firms, special economic zones, hotel owners and operators, free zones from UAE and rest of GCC and solution providers.
MarketsandMarkets is hosting an inaugural Microbiome - Advanced Therapeutics and Sequencing Congress on September 19 - 20 2019 in Philadelphia, USA gathering pharma, biotech, academicians and investors to exchange views and observe most ingenious microbiome research and technologies.
Over the two days, the congress will address:
Last year, the 4th Edition of this Conference focused on addressing the gaps between early-stage biomarker development and the commercialization stage of biomarkers. Leading industry and academic experts shared their case studies focusing on advancements in the companion diagnostics area. Designed to deliver a forward-looking perspective on the opportunities and challenges impacting market growth for the biomarker industry, the conference will focus on Biomarker Discovery & exploratory Biomarkers and application of biomarkers in Immuno-oncology, neurology and inflammatory diseases.
Since our past editions we dedicated our focus on the latest developments and addressed various applications of CRISPR as a molecular tool, gene expression, knock-in, genomic screening, along with therapeutic developments through animal modeling. Attended by 100+ genome editing professionals and 20+ gene expert speakers, the event saw participation of big companies like Casebia Therapeutics, Genentech, BMS, Cellectis , University of Laval, University of California, Center of Advanced Genome Engineering, Georgia Tech, Stanford University, Locana, Harvard Medical School, Agility, Poseida, Vertex, Ligandal, Integrated DNA Technologies, GE Healthcare, Cellecta, Agilent, Advanced Analytical, Thermofisher, Atum, Synthego, New England Biolabs, Aldevron, Applied Stem Cell and more.
In a constantly evolving innovative time, companies continue to wrestle for deriving more value from their “business and corporate strategies”. The significance of a business strategy relies on it being a viable way to build up business desires, creating a competitive advantage and additionally increment shareholder value to something beyond the aggregate of its physical resources. MarketsandMarkets Chief Strategy Officer Forum invites leading strategy decision makers who are making the future.
Last year, the 3rd Annual Next Gen Immuno-Oncology Congress discussed the latest updates in the development of Monoclonal Antibodies, ADC’s, Bispecific Antibodies, Immune Checkpoint inhibitors, and Cellular Therapy. The Congress also focused on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccine development and personalized immunotherapy.
Around 1 in 20 (6%) of patients are affected by preventable harm in medical care, of which around 12% causes permanent disability or death, according to a study published by The BMJ. These infections are contracted by an estimated 1.7 million patients annually and responsible for 99,000 deaths each year.
Preventing disease and controlling spread of resistant bacteria is of major importance when tackling antibiotic resistance. Already, AMR infections are estimated to cause 700,000 deaths each year globally, which is predicted to rise to 10 million, alongside a cumulative cost of $100 trillion, by 2020 if no action is taken.
According to a study published by The Lancet Infectious Diseases, researchers estimated that globally 3 in every 1,000 people carry latent multidrug-resistant tuberculosis (MDR-TB), with the prevalence of being 10 times higher among children younger than 15 years of age.
As outlined in the independent review on Antimicrobial Resistance, AMR is predicted to kill 10 million people every year by 2050 without action. From rare pathogens to pandemic prevention, explore the latest techniques and technologies that are shaping today’s diagnosis and treatment of infectious diseases.